During the holy month this year, public health experts from the University of Michigan Rogel Cancer Center are partnering with the Dearborn-based nonprofit ACCESS on a culturally tailored smoking cessation campaign called Yallah Quit. Yallah is Arabic for “Let’s go!”
About a third of advanced prostate cancers don’t respond to drugs like enzalutamide. A multi-institutional clinical trial is shedding new light on these non-responsive tumors -- pointing toward unique molecular characteristics that might be targetable with new therapeutic approaches.
The University of Michigan’s OncCOVID app draws on global cancer and coronavirus data to help people assess the risks to their lives by delaying cancer treatment.
A new analytic tool developed by University of Michigan Rogel Cancer Center researchers combines multiple data sets to help sift the signal from the noise. Called transPRECISE, it can identify pre-clinical systems or potential treatments for multiple cancer types
With no national data source, a University of Michigan-led study has uncovered frequent spills, inconsistent PPE use and problems with closed-system transfer devices across 12 institutions.
A team of scientists led by the University of Michigan Rogel Cancer Center and Case Comprehensive Cancer Center has identified the binding site where drug compounds could activate a key braking mechanism against the runaway growth of many types of cancer.
MENU